In conclusion, it is found in this study that erdosteine is able to repress the progression of middle ear effusion of otitis media in rats by modulating the TLR4 pathway, and the therapeutic effect and prognosis can be evaluated through the TLR4 pathway. Here, TLR4 is linked to otitis media.